LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
![Foto de LUIS GONZAGA](/img/nophoto.png)
![Foto de Universidad de Sevilla](/img/noimage_org.png)
Universidad de Sevilla
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Sevilla (24)
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy
International Journal of Molecular Sciences, Vol. 24, Núm. 18
2021
-
Identification of predictive biomarkers of response to hsp90 inhibitors in lung adenocarcinoma
International Journal of Molecular Sciences, Vol. 22, Núm. 5, pp. 1-18
2018
-
Erratum: Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung (Journal of Clinical Oncology (2017) DOI: 10.1200/JCO.2016.69.2160)
Journal of Clinical Oncology
-
Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer
Oncotarget, Vol. 9, Núm. 28, pp. 19945-19960
-
Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer
Oncotarget, Vol. 9, Núm. 4, pp. 4395-4410
-
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Journal of Experimental and Clinical Cancer Research, Vol. 37, Núm. 1
-
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction
Scientific Reports, Vol. 8, Núm. 1
-
Venous thromboembolism with EGFR monoclonal antibody necitumumab in stage IV non-small cell lung cancer: A retrospective cohort analysis
Thrombosis Research, Vol. 167, pp. 50-56
2017
-
Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer
Oncotarget, Vol. 8, Núm. 62, pp. 105196-105210
-
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement
Clinical Lung Cancer, Vol. 18, Núm. 6, pp. 667-674.e1
-
Results from the Phase III Randomized Trial of Onartuzumab plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung
Journal of Clinical Oncology, Vol. 35, Núm. 4
2016
-
Clinicopathologic features of advanced squamous NSCLC
Journal of Thoracic Oncology, Vol. 11, Núm. 9, pp. 1411-1422
2015
-
Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer
PLoS ONE, Vol. 10, Núm. 3
-
Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer
Oncotarget, Vol. 6, Núm. 8, pp. 6151-6159
-
Immunologic checkpoint blockade in lung cancer
Seminars in Oncology, Vol. 42, Núm. 3, pp. 402-417
-
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): An open-label, randomised, controlled phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 7, pp. 763-774
2014
-
MicroRNA clusters: Dysregulation in lung adenocarcinoma and COPD
European Respiratory Journal, Vol. 43, Núm. 6, pp. 1740-1749
-
MicroRNA-dependent regulation of transcription in non-small cell lung cancer
PLoS ONE, Vol. 9, Núm. 3
2013
-
Identification of proteomic signatures associated with lung cancer and COPD
Journal of Proteomics, Vol. 89, pp. 227-237